Great strides have been made in the treatment of Antl-Neutrophil Cytoplasmic Autoantibody (ANCA) - associated glomerulonephritis and small vessel vasculitis (ANCA disease). However major challenges remain In the form of mortality, and Irreversible organ damage, elevated rates of disease relapse and significant risks of severe adverse effects from current conventional therapy. New concepts have recently emerged from In vitro and animal studies that pertain to the mechanisms by which ANCA are induced, and those detailing their role in the vascular Injury leading to glomerulonephritis and vasculitis. Our group has introduced strong evidence in support of (1) the important role of complement activation in the pathogenesis of ANCA disease in the mouse model, (2) epigenetic dysregulation leading to aberrant expression of the leukocyte myeloperoxidase and PRS genes as a possible mechanism of disease relapse, and (3) protein complementarity as a trigger to autoimmunity to proteinase 3 (PR3) and plasminogen. The newly discovered antlplasmlnogen antibodies inhibit fibrin degradation and are hypothesized to contribute to the increased risk of thromboembolic event seen In patients with ANCA disease. The ultimate test of relevance of these new concepts lies in their applicability to human disease. The overall goal of this project is to test the impact of our advances on the treatment of ANCA disease through novel approaches to therapy. We will do so through two proof of concept, interventional, open label, randomized and controlled clinical trials.
Specific Aim 1 will test the novel concept of inhibiting complement activation in patients with active de novo or relapsing disease using the monoclonal antibody to complement factor C5, Ecullzumab (Sollris?) as an adjunct to conventional induction therapy.
Specific Aim 2 will test the concept of modulating autoantigen gene expression on the course of disease using all-trans retinoic acid (tretinoin) as an adjunct to conventional maintenance therapy in patients with mild or moderate disease activity. In a screening cohort study, Specific Aim 3 will test the impact of the anti-plasminogen autoantibodies on the detection and risk of thromboembolic events, a well recognized complication of ANCA disease.

Public Health Relevance

Several findings emerged from our laboratory and animal studies that fundamentally alter our understanding of the mechanisms of ANCA disease. In this project, we will test their applicability to patient treatment in 2 proof of concept clinical trials using FDA-approved agents. We will also test the impact of the newly identified, anti-plasminogen antibodies on the occurrence of clotting complications of ANCA disease. The novel therapeutic concepts developed in this project may extend to other autoimmune diseases.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1-GRB-R)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
McCall, A Scott; Bhave, Gautam; Pedchenko, Vadim et al. (2018) Inhibitory Anti-Peroxidasin Antibodies in Pulmonary-Renal Syndromes. J Am Soc Nephrol 29:2619-2625
Alba, Marco A; Jennette, J Charles; Falk, Ronald J (2018) Pathogenesis of ANCA-Associated Pulmonary Vasculitis. Semin Respir Crit Care Med 39:413-424
Weiner, Maria; Bjørneklett, Rune; Hrušková, Zdenka et al. (2018) Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. Nephrol Dial Transplant :
van Daalen, Emma E; Jennette, J Charles; McAdoo, Stephen P et al. (2018) Predicting Outcome in Patients with Anti-GBM Glomerulonephritis. Clin J Am Soc Nephrol 13:63-72
Thorpe, Carolyn T; Thorpe, Joshua M; Jiang, Tao et al. (2018) Healthcare utilization and expenditures for United States Medicare beneficiaries with systemic vasculitis. Semin Arthritis Rheum 47:507-519
Alba, Marco A; Flores-Suárez, Luis Felipe; Henderson, Ashley G et al. (2017) Interstital lung disease in ANCA vasculitis. Autoimmun Rev 16:722-729
Cortazar, Frank B; Pendergraft 3rd, William F; Wenger, Julia et al. (2017) Effect of Continuous B Cell Depletion With Rituximab on Pathogenic Autoantibodies and Total IgG Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol 69:1045-1053
Payan Schober, Fernanda; Jobson, Meghan A; Poulton, Caroline J et al. (2017) Clinical Features and Outcomes of a Racially Diverse Population with Fibrillary Glomerulonephritis. Am J Nephrol 45:248-256
Jones, Britta E; Yang, Jiajin; Muthigi, Akhil et al. (2017) Gene-Specific DNA Methylation Changes Predict Remission in Patients with ANCA-Associated Vasculitis. J Am Soc Nephrol 28:1175-1187
Merkel, Peter A; Xie, Gang; Monach, Paul A et al. (2017) Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. Arthritis Rheumatol 69:1054-1066

Showing the most recent 10 out of 86 publications